SAN FRANCISCO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman ...


SAN FRANCISCO, Jan.  23, 2026  (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company’s previously expressed “high confidence” in its 2025 revenue targets.  The firm urges investors who suffered significant losses to submit your ZBH losses now and visit Hagens Berman’s case page to view our latest investigation summary: www.hbsslaw.com/cases/zimmer-biomet-holdings-inc-zbh-investigation  The investigation focuses on whether Zimmer Biomet senior management may have misled investors regarding the stability of its international business. Despite August 2025 assurances of “very high” confidence in second-half growth, the company revealed on November 5, 2025, that it experienced distributor order cancellations in emerging markets and a significant revenue miss in Latin America. This news triggered a 15% stock tumble, wiping out significant market value and prompting the CEO to concede the company must be “far more measured” in its external commentary.  “We are investigating the apparent contrast between management’s August claims and the subsequent admission of serious headwinds that allegedly emerged during the same quarter,” said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.  Zimmer Biomet (ZBH) Investigation: Forecasting Failures and the Emerging Markets Headwind  The investigation centers on whether Zimmer Biomet violated federal securities laws by issuing overly optimistic guidance while concealing operational disruptions.  The August “High Confidence” Statements: On the company’s August 7, 2025 Q2 2025 earnings call, management assured investors that its updated 2025 year-over-year organic revenue growth forecast of 3.5% to 4.5% would be achieved in large part because of “the emerging markets distributor purchase[]” and said “I’ll be very surprised if Q3 is not a number scratching 6%.” Management also assured investors that “I have more conviction in our strategy and team than ever” and “our confidence in the second half revenue growth expectation is very high.” These statements drove the price of the company shares up over 7% that day.Revealed Cancelled Orders and Governance & Leadership Changes: On November 5, 2025, Zimmer Biomet reported its results for Q3 2025 revealing that year-over-year organic revenue growth was just 5%. The company also reduced its top-line organic revenue growth forecast to 4% and revealed that “emerging markets represented a headwind to growth.” Zimmer Biomet revealed that during the quarter it experienced distributor orders cancelations in emerging markets, mainly the Middle East and Eastern Europe, it widely missed its forecast in Latin America, and it is “making leadership and governance changes in some of our international businesses to address some of the headwinds that we’ve seen in these geographies throughout the year 2025.”CEO’s Guidance Pivot: In response to analyst’s scrutiny during the same November 5 earnings call, CEO Ivan Tornos stated that “effective today” “we, or rather I need to be far more measured in our external commentary.” The market swiftly reacted, sending the price of Zimmer Biomet shares down 15% that day.  Next Steps: Contact Partner Reed Kathrein Today  Hagens Berman is a top-tier plaintiff litigation firm recognized for prosecuting securities class action litigation.  Mr. Kathrein is actively advising investors who purchased ZBH shares and suffered substantial losses following the November 5, 2025 crash.  TO SUBMIT YOUR ZIMMER BIOMET (ZBH) LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:  Report Your ZBH Investment Losses to HBSSContact: Reed Kathrein at 844-916-0895 or email ZBH@hbsslaw.com  Whistleblowers: Persons with non-public information regarding Zimmer Biomet should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ZBH@hbsslaw.com.  About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.   Contact: Reed Kathrein, 844-916-0895  
            

ZBH Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and “Inconsistent” Execution

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN FRANCISCO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Hagens Berman&#039;s investigation into Zimmer Biomet (ZBH) highlights management&#039;s missteps regarding revenue forecasts and emerging market challenges, which have led to questions about their statements and a significant stock price drop. The ongoing scrutiny may impact investor confidence and ZBH&#039;s operational direction moving forward.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Hagens Berman investigates ZBH for misleading revenue forecasts.</li><li>Management&#039;s confidence in 2025 revenue now questioned after market miss.</li><li>ZBH&#039;s stock fell 15% after revealing international market headwinds.</li><li>Leadership changes announced to address emerging market challenges.</li><li>Investors invited to report losses due to alleged mismanagement.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Hagens Berman</strong>: Investigating ZBH for potential securities law violations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This situation falls under &#039;Corporate Developments&#039; as it involves investigations into ZBH’s executive management and financial guidance, signaling potential unrest within the company&#039;s governance structure.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ZBH&#039;s stock price significantly impacted by 15% drop after recent disclosures.</li><li>Ongoing investigations could lead to further declines if mismanagement is confirmed.</li><li>Leadership changes may not restore investor confidence despite operational adjustments.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ZBH stock plummeted 15% post-earnings announcement on November 5, 2025.</li><li>The company&#039;s revised revenue growth forecast reduced from 3.5%-4.5% to 4%.</li><li>Distributor cancellations were primarily in emerging markets like the Middle East.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting ZBH stocks as further scrutiny may lead to additional losses in the near term.</p>
  </section>
</section>


<article>
    <h2>Hagens Berman Investigates Zimmer Biomet (ZBH) Over Revenue Targets and Emerging Market Issues</h2>
    <p>On January 23, 2026, the national shareholder rights law firm Hagens Berman announced an investigation into Zimmer Biomet Holdings, Inc. (NYSE: ZBH). This inquiry follows disclosures that have raised concerns about the foundations of the company’s previously stated "high confidence" in achieving its 2025 revenue targets. The firm is calling on investors who have incurred losses to submit their claims, as they explore potential misleading statements made by senior management regarding the company's international operations.</p>

    <section>
        <h3>Key Findings of the Investigation</h3>
        <p>The investigation primarily focuses on whether Zimmer Biomet violated federal securities laws by providing overly optimistic revenue forecasts while failing to disclose significant operational challenges. This inquiry was sparked by two critical announcements made by the company:</p>
        <ul>
            <li><strong>September 2025 Report:</strong> Zimmer Biomet reported a notable revenue miss and the cancellations of distributor orders in emerging markets.</li>
            <li><strong>CEO's Admission:</strong> Following scrutiny from analysts, CEO Ivan Tornos acknowledged the need for the company to adopt a “far more measured” approach in external communications.</li>
        </ul>
    </section>

    <section>
        <h3>August Assurances vs. November Revelations</h3>
        <p>During the Q2 2025 earnings call on August 7, 2025, Zimmer Biomet's management expressed strong optimism about their financial forecast. They projected a year-over-year organic revenue growth of 3.5% to 4.5%, citing confidence in emerging markets as a key driver.</p>
        <blockquote>
            <p>“I’ll be very surprised if Q3 is not a number scratching 6%,” said Tornos, emphasizing his conviction in the company’s strategy.</p>
        </blockquote>
        <p>However, this confidence starkly contrasted with the reality revealed on November 5, 2025, when the company announced a significantly reduced forecast. They reported only <strong>5%</strong> organic revenue growth for the quarter, leading to a drastic decline in ZBH shares, which fell by <strong>15%</strong> in response to this disappointing news.</p>
    </section>

    <section>
        <h3>Impact on Investors</h3>
        <p>The recent turn of events has raised serious questions among investors about Zimmer Biomet's past claims and its ability to execute on its strategic goals. The firm’s recognition of challenges in emerging markets, particularly in the Middle East and Eastern Europe, adds to the uncertainty surrounding the stock. Hagens Berman's partner Reed Kathrein stated:</p>
        <blockquote>
            <p>“We are investigating the apparent contrast between management’s August claims and the subsequent admission of serious headwinds that allegedly emerged during the same quarter.”</p>
        </blockquote>
        <p>With these developments, investors who purchased ZBH shares are encouraged to report their investment losses to Hagens Berman promptly.</p>
    </section>

    <section>
        <h3>Next Steps for Investors</h3>
        <p>Investors who believe they have suffered losses related to Zimmer Biomet's recent disclosures are urged to contact Reed Kathrein directly at <strong>844-916-0895</strong> or via email at <a href="mailto:ZBH@hbsslaw.com">ZBH@hbsslaw.com</a> for assistance. Hagens Berman is widely recognized for its success in prosecuting securities class action litigation and advocating for investors.</p>
        <p>In addition, whistleblowers possessing non-public information about Zimmer Biomet might consider options to assist in the investigation. Under the SEC Whistleblower program, individuals who provide original information may receive rewards totaling up to <strong>30%</strong> of any successful recovery resulting from their input.</p>
    </section>

    <section>
        <h3>About Hagens Berman</h3>
        <p>Hagens Berman is a prominent plaintiffs’ rights law firm known for its dedication to corporate accountability. The firm has successfully secured over <strong>$2.9 billion</strong> in compensation for clients impacted by corporate malfeasance. More information about their work can be found at <a href="http://hbsslaw.com">hbsslaw.com</a>.</p>
    </section>
</article>

Hagens Berman's investigation into Zimmer Biomet (ZBH) highlights management's missteps regarding revenue forecasts and emerging market challenges, which have led to questions about their statements and a significant stock price drop. The ongoing scrutiny may impact investor confidence and ZBH's operational direction moving forward.

ZBH Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and “Inconsistent” Execution

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News